10-Q: CVS Health Reports Q3 Loss Amid $5.7B Goodwill Impairment

CVS Health reported a significant net loss in Q3 2025, primarily driven by a $5.7 billion goodwill impairment charge related to its Health Care Delivery unit, despite overall revenue growth.

Summary

• Total revenues increased by 7.8% to $102.87 billion for the three months ended September 30, 2025, compared to $95.43 billion in the prior year.
• The company reported a net loss attributable to CVS Health of $3.98 billion, or $3.13 per diluted share, for Q3 2025, a significant decline from net income of $87 million, or $0.07 per diluted share, in Q3 2024.
• Operating income shifted to a loss of $3.21 billion in Q3 2025, down from an operating income of $832 million in Q3 2024, primarily due to a $5.7 billion goodwill impairment charge.
• The Health Care Benefits segment saw adjusted operating income improve to $314 million in Q3 2025 from a loss of $924 million in Q3 2024, with its Medical Benefit Ratio (MBR) decreasing to 92.8% from 95.2%.
• The Health Services segment's adjusted operating income decreased by 7.0% to $2.05 billion in Q3 2025, impacted by continued pharmacy client price improvements and a $83 million clinic closure charge.
• The Pharmacy & Consumer Wellness segment's adjusted operating income decreased by 7.4% to $1.48 billion in Q3 2025, despite a 6.9% increase in prescriptions filled and 16.8% pharmacy same-store sales growth.
• CVS Health deconsolidated its Omnicare Entities (long-term care pharmacy operations) due to Chapter 11 bankruptcy proceedings, resulting in a $483 million gain on deconsolidation.
• The company acquired prescription files and certain stores from Rite Aid for $465 million during the third quarter of 2025.
• CVS Health plans to exit the states in which Aetna operates on the individual public health insurance exchanges effective January 2026.
• The company recorded $1.22 billion in legacy litigation charges and a $320 million opioid litigation charge during the nine months ended September 30, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the substantial net loss and operating loss driven by a $5.7 billion goodwill impairment charge. While revenue growth was positive, and the Health Care Benefits segment showed improvement, the significant write-down in the Health Services segment, coupled with ongoing litigation charges and declining Medicare Advantage star ratings, indicates considerable operational and strategic challenges. The future outlook also highlights persistent utilization pressures and potential for further goodwill impairment.

Positives

• Total revenues increased by 7.8% in Q3 2025 and 7.7% for the nine months ended September 30, 2025, demonstrating strong top-line growth across all operating segments.
• The Health Care Benefits segment significantly improved its adjusted operating income to $314 million in Q3 2025 from a loss of $924 million in Q3 2024, driven by a lower Medical Benefit Ratio (92.8% vs. 95.2%) and improved underlying performance in the Government business.
• The Pharmacy & Consumer Wellness segment reported strong pharmacy same-store sales growth of 16.8% and a 6.9% increase in prescriptions filled in Q3 2025, benefiting from drug mix (including GLP-1 drugs) and Rite Aid acquisitions.
• The deconsolidation of Omnicare Entities resulted in a $483 million gain, simplifying the company's structure.
• Net cash provided by operating activities remained consistent at $7.25 billion for the nine months ended September 30, 2025.
• The company expects benefits from ongoing enterprise-wide cost savings initiatives, aiming for over $500 million in savings in 2025.

Negatives

• CVS Health reported a net loss attributable to CVS Health of $3.98 billion in Q3 2025 and $1.18 billion for the nine months ended September 30, 2025, a substantial decline from prior year's net income.
• A $5.7 billion goodwill impairment charge was recorded in Q3 2025 related to the Health Care Delivery reporting unit (Signify Health and Oak Street Health), indicating challenges in these acquired assets.
• Operating income shifted to a loss of $3.21 billion in Q3 2025, a significant decrease from $832 million in operating income in Q3 2024.
• Diluted EPS fell to a loss of $3.13 in Q3 2025 and $0.93 for the nine months, compared to positive EPS in the prior year periods.
• The Health Services segment's adjusted operating income decreased by 7.0% in Q3 2025 and 4.6% for the nine months, primarily due to continued pharmacy client price improvements and higher medical benefit ratio in health care delivery.
• Medical membership in the Health Care Benefits segment decreased by 445,000 members year-over-year to 26.7 million as of September 30, 2025, reflecting declines in the individual exchange product line.
• Medicare Advantage star ratings for 2026 declined, with over 81% of members in plans with at least 4.0 stars, down from 88% for 2025.
• The company incurred $1.22 billion in legacy litigation charges and a $320 million opioid litigation charge during the nine months ended September 30, 2025.
• A $83 million Health Care Delivery clinic closure charge was recorded in Q3 2025 related to planned closures of certain Oak Street Health clinics in 2026.
• The effective income tax rate was significantly impacted by the non-deductible goodwill impairment and legacy litigation charges, resulting in a negative rate for Q3 and a very high rate for the nine months.

Risks

• Persistent elevated utilization levels are expected to pressure the Health Care Benefits segment and health care delivery assets in the Health Services segment for the remainder of the year, with potential for future goodwill impairment.
• Increases in utilization beyond projections may require additional premium deficiency reserves within the Health Care Benefits segment.
• The Medicaid business is experiencing medical cost pressures due to higher acuity following member redeterminations, with uncertainty on when state rate updates will fully offset these pressures.
• The individual exchange business is subject to volatility from the risk adjustment program and changes in the company's risk relative to market risk.
• Continued sharing of a larger portion of rebates, fees, and discounts with clients, and limitations on offering retail network differential or spread, may adversely affect PBM profitability.
• Regulatory changes or shifts in consumer sentiment for immunizations could negatively impact national demand and financial results.
• Implementation of new tariffs or changes in tariffs could lead to increased costs, supply chain disruptions, and adverse impacts on consumer demand and financial results.
• Consumer spend management and a shift to value, grocery, and digital retailers could drive lower front store sales.
• Changes in U.S. and global capital markets can significantly affect interest rates and financing costs.
• Actions by ratings agencies, including potential downgrades (Fitch and S&P outlook Negative), could impact future borrowing costs, access to capital markets, and new store operating lease costs.
• Legislation and/or regulations seeking to regulate PBM activities could adversely affect the company's ability to conduct business on commercially reasonable terms and standardize products.
• The remaining goodwill balance of approximately $4.2 billion in the Health Care Delivery reporting unit could be impaired again if financial forecasts are not met, given that its fair value and carrying value were the same as of September 30, 2025.
• Ongoing legal proceedings, including usual and customary pricing litigation, PBM litigation, controlled substances litigation, prescription processing litigation, provider proceedings, and CMS audits, could result in substantial unanticipated verdicts, fines, or sanctions.

Future Outlook

The company anticipates continued pressure on its Health Care Benefits and Health Services segments due to persistently elevated utilization levels, which could lead to future goodwill impairment. It expects to exit individual public health insurance exchanges by January 2026 and faces medical cost pressures in its Medicaid business. The Pharmacy & Consumer Wellness segment is expected to benefit from incremental volume due to retail pharmacy market disruption. The company aims for over $500 million in cost savings in 2025 from enterprise-wide initiatives. Debt ratings and capital market conditions remain a factor for future financing costs.

Management Comments

• The company is creating new sources of value through its integrated model, expanding into personalized, technology-driven care delivery and health services to increase access to quality care, deliver better health outcomes, and lower overall health care costs.
• The company made a number of changes to its Health Care Delivery management team during 2025 to best respond to challenges, including persistent elevated utilization levels.
• The new Health Care Delivery management team finalized strategic changes, including reducing the number of new primary care clinics to open in 2026 and annually thereafter, and closing certain existing Oak Street Health clinics in 2026.
• The company believes its operating cash flows, commercial paper program, credit facilities, and potential future borrowings will be sufficient to fund future payments and long-term initiatives.
• The company believes its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on its financial position.

Industry Context

The healthcare industry continues to face challenges from elevated utilization levels, impacting profitability for health insurers and care providers. Regulatory scrutiny on Pharmacy Benefit Managers (PBMs) regarding drug pricing and rebates remains high, leading to ongoing investigations and litigation. The shift towards value-based care and integrated health solutions is a key trend, but the company's goodwill impairment in its Health Care Delivery unit highlights the difficulties in executing these strategies. The retail pharmacy market is experiencing disruption, which CVS Health is leveraging through acquisitions like Rite Aid's prescription files, while also facing reimbursement pressures.

Comparison to Industry Standards

• The decline in Medicare Advantage star ratings for 2026 (81% of members in >=4.0 star plans vs. 88% for 2025) suggests a potential underperformance compared to industry leaders who consistently maintain high star ratings, which are crucial for bonus payments and member retention.
• The $5.7 billion goodwill impairment related to the Health Care Delivery unit (Signify Health and Oak Street Health) indicates that the company's acquisitions in value-based care may not be performing to initial expectations, contrasting with other integrated health systems that have shown more robust growth and synergy realization in similar ventures.
• The Medical Benefit Ratio (MBR) improvement in Health Care Benefits to 92.8% from 95.2% is a positive sign, potentially outperforming some competitors struggling with higher medical costs, though specific peer comparisons are not provided in the filing.
• The company's decision to exit individual public health insurance exchanges effective January 2026 suggests a strategic realignment, potentially ceding market share to competitors like Centene or UnitedHealth Group who remain active and profitable in these markets.
• The ongoing PBM litigation and regulatory investigations, including the FTC's administrative complaint regarding insulin costs, place CVS Health among other large PBMs (e.g., Express Scripts, OptumRx) facing similar scrutiny over pricing practices and rebate arrangements, indicating a systemic industry challenge rather than an isolated company issue.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing lawsuits alleging that retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price, including putative class actions and state false claims act claims.
• Multiple lawsuits and investigations (FTC, DOJ, state Attorneys General) concerning PBM practices, drug pricing, rebate arrangements with manufacturers, and alleged anti-competitive practices, including an FTC administrative complaint regarding insulin costs.
• A court ruled the company liable under the False Claims Act for certain claims in United States ex rel. Behnke v. CVS Caremark Corporation, et al., resulting in a $291 million judgment (trebled damages and penalties), which the company has appealed.
• Settlement resolving substantially all opioid claims against company entities by 45 states, the District of Columbia, and eligible U.S. territories, with ongoing litigation in non-participating jurisdictions.
• A jury found Omnicare and CVS Health Corporation liable for False Claims Act violations in U.S. ex rel. Bassan et al. v. Omnicare, Inc. and CVS Health Corp., with Omnicare liable for $136 million (trebled to $407 million) plus $542 million in penalties, and CVS Health Corporation jointly and severally liable for $165 million of the penalties; the company has appealed.
• Ongoing investigations and subpoenas from the DOJ regarding risk adjustment payments under Medicare Parts C and D, and false claims submitted to Medicare in connection with prescription drug reimbursements under Medicare Part D.
• DOJ intervened in a qui tam case alleging kickbacks to insurance brokers to induce them to direct patients to Medicare Advantage plans and discriminatory conduct.
• Purported class actions and individual lawsuits alleging underpayment for out-of-network services, failure to timely pay or administer claims, and other issues related to provider payments.
• CMS is conducting Risk Adjustment Data Validation (RADV) audits of Medicare Advantage plans, with potential for refunds if risk-adjusted premiums are not properly supported by medical record data, and plans to audit every Medicare Advantage contract each payment year from 2018 through 2024 by early 2026.
• Stockholder class action and derivative complaints alleging omissions and misrepresentations related to the performance of the long-term care (LTC) business unit, opioid oversight, and the profitability of the Health Care Benefits segment.

Stakeholder Impact

• **Shareholders**: Significant negative impact due to the $3.98 billion net loss and $3.13 diluted EPS loss in Q3 2025, driven by the goodwill impairment. Ongoing litigation and declining Medicare Advantage star ratings could further impact shareholder value. Share repurchase programs remain authorized but no repurchases occurred in the current period.
• **Employees**: Impacted by changes to the Health Care Delivery management team, planned closures of certain Oak Street Health clinics in 2026 (resulting in severance and employee-related costs), and ongoing enterprise-wide cost savings initiatives which may include workforce optimization.
• **Customers/Members**: Medical membership declined in Medicare and individual exchange products. The exit from individual public health insurance exchanges will affect members in those states. Changes in PBM practices and pricing, as well as potential impacts from litigation, could affect drug costs and access to services. Medicare Advantage members are affected by changes in star ratings, which influence plan quality and bonus payments.
• **Suppliers/Providers**: PBM practices, including rebate arrangements and pharmacy contracting, are under scrutiny and litigation, potentially impacting relationships and reimbursement for pharmaceutical manufacturers and retail pharmacies. Providers are also affected by litigation regarding claims payments and out-of-network services.
• **Creditors**: The company issued $4.0 billion in senior notes to repay existing indebtedness, indicating active debt management. Debt ratings (Fitch and S&P outlook Negative) could impact future borrowing costs and access to capital, which is relevant for creditors.

Next Steps

• Reduce the number of new primary care clinics to open in 2026 and annually thereafter.
• Close certain existing Oak Street Health clinics in 2026.
• Exit the states in which Aetna operates on the individual public health insurance exchanges effective January 2026.
• Continue to work closely with state partners to ensure underlying medical cost trends in the Medicaid business are reflected in premium rates.
• Evaluate and adjust approach in each market served, considering competitive demand, legislative/regulatory factors, and labor/market dynamics.
• Implement ongoing enterprise-wide cost savings initiatives to streamline and simplify the organization, improve efficiency, and reduce costs, targeting over $500 million in savings in 2025.
• Defend against ongoing legal proceedings, including usual and customary pricing litigation, PBM litigation, controlled substances litigation, and prescription processing litigation.
• Cooperate with government investigations and subpoenas from agencies like the DOJ, HHS, and FTC.
• Monitor and respond to CMS RADV audits of Medicare Advantage contracts, with audits for payment years 2018 through 2024 expected to be completed by early 2026.
• The Board's demand review committee will evaluate stockholder demands related to opioid oversight and the Health Care Benefits segment's profitability.

Key Dates

Recommendation

The filing reveals a deeply concerning financial performance, marked by a substantial net loss of $3.98 billion and a $3.13 diluted EPS loss in Q3 2025. The primary driver, a $5.7 billion goodwill impairment related to the Health Care Delivery unit (Signify Health and Oak Street Health), signals significant overvaluation of recent acquisitions and challenges in integrating and monetizing these assets. This impairment, coupled with planned clinic closures and reduced expansion, indicates a fundamental re-evaluation of the growth strategy in a key segment. Furthermore, the company faces a barrage of costly litigation, including $1.22 billion in legacy charges and $320 million in opioid-related charges, which will continue to drain resources and create uncertainty. Declining Medicare Advantage star ratings and medical membership losses in critical segments suggest competitive pressures and potential future revenue headwinds. While revenue growth is present, it is overshadowed by profitability issues and strategic missteps. The negative outlook from Fitch and S&P on long-term debt further underscores financial fragility. A seasoned investor would view these results as a strong indicator of underlying operational and strategic issues, warranting a 'sell' recommendation to mitigate further downside risk until a clear path to sustainable profitability and successful integration of growth initiatives is demonstrated.

Keywords

CVS Health, 10-Q, Quarterly Report, Goodwill Impairment, Health Care Delivery, Oak Street Health, Signify Health, Net Loss, Revenue Growth, Health Care Benefits, Health Services, Pharmacy & Consumer Wellness, PBM, Medicare Advantage, Medicaid, Omnicare, Rite Aid Acquisition, Litigation, Opioid Settlement, Risk Adjustment, Utilization Trends, Financial Results